Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Merck |
---|---|
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00293254 |
This study will investigate the safety and efficacy of raltegravir as a therapy for HIV-infected patients failing current therapy.
Condition | Intervention | Phase |
---|---|---|
HIV Infections |
Drug: Comparator: raltegravir potassium Drug: Comparator: placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety Study |
Official Title: | A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK0518 in Combination With an Optimized Background Therapy (OBT), Versus Optimized Background Therapy Alone, in HIV-Infected Patients With Documented Resistance to at Least 1 Drug |
Estimated Enrollment: | 351 |
Study Start Date: | February 2006 |
Estimated Study Completion Date: | June 2011 |
Estimated Primary Completion Date: | April 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
raltegravir potassium
|
Drug: Comparator: raltegravir potassium
raltegravir potassium 400 mg tablet P.O. b.i.d. with optimized background therapy. Treatment period of 48 weeks.
|
2: Placebo Comparator
Placebo
|
Drug: Comparator: placebo
Placebo tablets P.O. b.i.d. with optimized background therapy. Treatment period of 48 weeks.
|
Ages Eligible for Study: | 16 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Merck & Co., Inc. ( Executive Vice President, Clinical and Quantitative Sciences ) |
Study ID Numbers: | 2005_097, MK0518-019 |
Study First Received: | February 15, 2006 |
Last Updated: | January 23, 2009 |
ClinicalTrials.gov Identifier: | NCT00293254 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Treatment Experienced |
Virus Diseases Sexually Transmitted Diseases, Viral HIV Infections Sexually Transmitted Diseases |
Acquired Immunodeficiency Syndrome Retroviridae Infections Immunologic Deficiency Syndromes |
Virus Diseases Sexually Transmitted Diseases, Viral RNA Virus Infections Slow Virus Diseases Immune System Diseases HIV Infections |
Sexually Transmitted Diseases Acquired Immunodeficiency Syndrome Lentivirus Infections Infection Retroviridae Infections Immunologic Deficiency Syndromes |